Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Chiome Bioscience Inc. ( (JP:4583) ) is now available.
Chiome Bioscience Inc. has entered a collaborative research agreement with OmniAb, Inc. to explore synergies in bispecific antibody generation. This partnership aims to implement a high throughput screening system, leveraging OmniAb’s OmniClic platform, to enhance Chiome’s antibody development capabilities and strengthen its profitability. The financial impact for the fiscal year ending December 2025 is expected to be minimal.
More about Chiome Bioscience Inc.
Chiome Bioscience Inc. operates in the biotechnology industry, focusing on the development of bispecific antibodies using its proprietary ADLib system. The company is launching an Integrated Drug Discovery (IDD) business aimed at enhancing antibody development.
YTD Price Performance: -37.55%
Average Trading Volume: 9,578,713
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen11.32B
Learn more about 4583 stock on TipRanks’ Stock Analysis page.